Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on March 20, 2017. The report discloses a material change in executive leadership regarding the Chief Financial Officer position.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of CFO: W. Bradford Smith resigned as Chief Financial Officer, effective March 31, 2017, to pursue other opportunities.
- Interim Appointment: James Fortune, the Company's Chief Operating Officer, will assume the roles of principal financial officer and principal accounting officer on an interim basis, effective April 1, 2017.
- Transition Support: Mr. Smith agreed to provide consulting services on an as-needed hourly basis through May 31, 2017, to assist with the transition.
Management Commentary and Risks
Mr. Fortune, age 58, has served as Chief Operating Officer since 2008. His background includes senior management roles at Augmenix, Inc., AccessClosure, Inc., Confluent Surgical, Inc., and Johnson & Johnson. The filing states there are no family relationships between Mr. Fortune and other officers or directors, and no undisclosed arrangements regarding his appointment.
Investor Verification Checklist
- Confirm the exact effective date of the CFO resignation (March 31, 2017) and the interim appointment (April 1, 2017).
- Verify the terms of the consulting agreement for the departing CFO, specifically the hourly basis and end date (May 31, 2017).
- Review Mr. Fortune's prior experience to assess his readiness for the interim financial leadership role.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.